Cargando…

Clinical characteristics of abruptly increased paediatric patients with Omicron BF.7 or BA.5.2 in Beijing

BACKGROUND: The coronavirus disease 2019 outbreak has hit Beijing since mid-Nov, 2022, with soaring growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among children. Therefore, it is vital to determine the clinical manifestations of epidemic SARS-CoV-2 strains in paediatric pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Lei, Wang, Congying, Li, Xiaoyun, Wang, Xinning, Kang, Yingying, Ma, Xiaomei, Sun, Rui, Sun, Yu, Zhu, Runan, Jia, Liping, Yao, Yao, Li, Xiaohui, Zhang, Daitao, Pan, Yang, Lv, Bing, Yuan, Jing, Zhao, Linqing, Gu, Qinglong, Zhang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492331/ https://www.ncbi.nlm.nih.gov/pubmed/37684638 http://dx.doi.org/10.1186/s12985-023-02177-x

Ejemplares similares

Evolutionary analysis of Omicron variant BF.7 and BA.5.2 pandemic in China
por: Sun, Yamin, et al.
Publicado: (2023)

The First Outbreak of Omicron Subvariant BA.5.2 — Beijing Municipality, China, July 4, 2022
por: Feng, Zhaomin, et al.
Publicado: (2022)

A Comparison of Clinical Characteristics of Infections with SARS-CoV-2 Omicron Subvariants BF.7.14 and BA.5.2.48 — China, October–December 2022
por: Huo, Da, et al.
Publicado: (2023)

Epidemiological and clinical features of children with the Omicron BA.5.2 subvariant in Guangzhou
por: Li, Feng, et al.
Publicado: (2023)

Identification of WU polyomavirus from pediatric patients with acute respiratory infections in Beijing, China
por: Zhao, Linqing, et al.
Publicado: (2009)

Emerging human respiratory syncytial virus genotype ON1 found in infants with pneumonia in Beijing, China
por: Cui, Guanglin, et al.
Publicado: (2013)

Effectiveness of first and second boost COVID-19 vaccination in healthy adults during BA.5.2/BF.7 surge in China
por: Zhang, Yongchang, et al.
Publicado: (2023)

Importation of SARS-CoV-2 Omicron variant in Beijing, China
por: Li, Fu, et al.
Publicado: (2022)

No Novel Prevalent Mutations Detected in the Circulating Strains of BF.7, BA.5.2, DY, and XBB — China, November 2022 to June 2023
por: Wang, Liang, et al.
Publicado: (2023)

The SARS-CoV-2 Hydra, a tiny monster from the 21st century: Thermodynamics of the BA.5.2 and BF.7 variants
por: Popovic, Marko
Publicado: (2023)

The First Case of Co-Infection with Omicron Subvariants BA.5.2.48 and BF.7.14 — Chongqing Municipality, China, February 2023
por: Su, Kun, et al.
Publicado: (2023)

Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2
por: Qu, Panke, et al.
Publicado: (2023)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2
por: Qu, Panke, et al.
Publicado: (2022)

Case report: Severe pneumonia and pneumomediastinum in a previously robust adolescent caused by Omicron BA.5.2
por: Xiang, Tianxin, et al.
Publicado: (2023)

Analysis of a super-transmission of SARS-CoV-2 omicron variant BA.5.2 in the outdoor night market
por: Luo, Mingyu, et al.
Publicado: (2023)

Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination(1)
por: Wang, Hongyu, et al.
Publicado: (2023)

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
por: Cao, Yunlong, et al.
Publicado: (2022)

COVID-19 Bivalent Booster in Pregnancy: Maternal and Neonatal Antibody Response to Omicron BA.5, BQ.1, BF.7 and XBB.1.5 SARS-CoV-2
por: Chen, Wei-Chun, et al.
Publicado: (2023)

BF.7 Omicron subvariant in India and China: a raising concern – correspondence
por: Sah, Ranjit, et al.
Publicado: (2023)

Corrigendum: Analysis of a super-transmission of SARS-CoV-2 omicron variant BA.5.2 in the outdoor night market
por: Luo, Mingyu, et al.
Publicado: (2023)

Genetic Evolution and Variation of Human Adenovirus Serotype 31 Epidemic Strains in Beijing, China, during 2010–2022
por: Liu, Liying, et al.
Publicado: (2023)

Is BF.7 more infectious than other Omicron subtypes: Insights from structural and simulation studies of BF.7 spike RBD variant
por: Singh, Jaikee Kumar, et al.
Publicado: (2023)

Low-temperature modification of Ba(BF(4))(2)(H(2)O)(3)
por: Goreshnik, Evgeny, et al.
Publicado: (2023)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2
por: Zhu, Airu, et al.
Publicado: (2023)

Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
por: Yang, Jinyoung, et al.
Publicado: (2023)

BF.7 Omicron subvariant (BA.5.2.1.7) posing fears of a rise in COVID-19 cases again: a critical appraisal and salient counteracting strategies
por: Dhama, Kuldeep, et al.
Publicado: (2023)

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
por: Wang, Qian, et al.
Publicado: (2023)

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies
por: Wang, Yingdan, et al.
Publicado: (2022)

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
por: Khan, Khadija, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Insight into Bacillus cereus Associated with Infant Foods in Beijing
por: Wang, Ping, et al.
Publicado: (2022)

Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5
por: Kawasuji, Hitoshi, et al.
Publicado: (2023)

Comparative analysis of clinical and immunological profiles across Omicron BA.5.2 subvariants using next-generation sequencing in a Chinese cohort
por: Huang, Jianliang, et al.
Publicado: (2023)

Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75
por: Cao, Yunlong, et al.
Publicado: (2022)

Covid-19 omicron variant infection in neonates of Guangdong province-a report of 52 cases
por: Yang, Yi-Kang, et al.
Publicado: (2023)

The changed endemic pattern of human adenovirus from species B to C among pediatric patients under the pressure of non-pharmaceutical interventions against COVID-19 in Beijing, China
por: Wang, Fangming, et al.
Publicado: (2023)

Possible threat of the Omicron subvariants XBB.1.5 and BF.7 to the Indian subcontinent: A correspondence
por: Ghosh, Shankhaneel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_eqk0jpre133kriru36v2f1ogp4